Liang Chen Jia Wen, Woerdenbag Herman J, Ekhart Corine, Vitalone Annabella, van Hunsel Florence P A M
Pharmacy Master Programme, School of Science and Engineering, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Pharmaceuticals (Basel). 2025 Aug 15;18(8):1208. doi: 10.3390/ph18081208.
: Natural products with claimed adaptogenic and/or immunomodulatory effects are widely used in traditional medicine systems across Eurasia. These include herbal remedies (e.g., ), fungi (e.g., ), and animal-derived substances (e.g., propolis from ). Despite their popularity, the safety profiles of these products-particularly concerning adverse events (AEs) and serious adverse events (SAEs)-remain insufficiently understood. This study aimed to assess the safety profiles of adaptogenic and immunomodulatory natural products through a scoping review of published human studies and an analysis of individual case safety reports (ICSRs) from the WHO-UMC VigiBase database. : A scoping review was conducted using PubMed (1980-2024) in line with PRISMA-ScR guidelines. Eligible studies included randomized and non-randomized clinical trials and case reports in humans focused on safety outcomes. Data extraction followed the Joanna Briggs Institute (JBI) standardized template. ICSRs from VigiBase were analyzed by product type, AE type and seriousness, and demographic characteristics. The data were further organized to highlight the 15 most frequently reported products and their top five System Organ Classes (SOCs) and Preferred Terms (PTs). : The scoping review identified 51 natural products with reported adaptogenic and/or immunomodulatory properties. This included 285 clinical trials and 119 case studies on single-ingredient products and 54 clinical trials and 21 case studies on multi-ingredient preparations. Common AEs included gastrointestinal, dermatological, hepatic, cardiovascular, and immunological reactions. SAEs were rare but reported for , , and From Vigibase, 45,042 ICSRs were retrieved for 49 natural products: 10,702 for single-ingredient and 34,340 for multi-ingredient products. Among 7856 reports listing a single-ingredient product as the sole suspect, 15.8% were SAEs, including eight fatal cases. However, the causality remained unclear due to insufficient data. , , and were most frequently associated with SAEs. In multi-ingredient products, propolis was frequently linked to hypersensitivity and skin reactions. : This study provides a comprehensive overview of the safety profiles of adaptogenic and immunomodulatory natural products. Variability in product composition, lack of standardization, incomplete reporting in clinical studies, and underreporting in pharmacovigilance databases complicate accurate risk assessment. For multi-ingredient products, attributing specific AEs to specific components remains difficult. Further high-quality clinical research and improved pharmacovigilance are needed, along with clear safety warnings to reduce risks for consumers.
宣称具有适应原性和/或免疫调节作用的天然产物在欧亚大陆的传统医学体系中被广泛使用。这些包括草药疗法(如……)、真菌(如……)和动物源性物质(如来自……的蜂胶)。尽管它们很受欢迎,但这些产品的安全性,尤其是关于不良事件(AE)和严重不良事件(SAE)的情况,仍未得到充分了解。本研究旨在通过对已发表的人体研究进行范围综述以及分析世界卫生组织药物不良反应数据库(WHO-UMC VigiBase)中的个体病例安全报告(ICSR)来评估具有适应原性和免疫调节作用的天然产物的安全性。
按照PRISMA-ScR指南,使用PubMed(1980 - 2024年)进行了范围综述。符合条件的研究包括关注安全性结果的人类随机和非随机临床试验以及病例报告。数据提取遵循乔安娜·布里格斯研究所(JBI)的标准化模板。对VigiBase中的ICSR按产品类型、AE类型和严重程度以及人口统计学特征进行了分析。数据进一步整理以突出15种报告频率最高的产品及其前五大系统器官分类(SOC)和首选术语(PT)。
范围综述确定了51种具有报告的适应原性和/或免疫调节特性的天然产物。这包括285项关于单一成分产品的临床试验和119项病例研究,以及54项关于多成分制剂的临床试验和21项病例研究。常见的AE包括胃肠道、皮肤、肝脏、心血管和免疫反应。SAE很少见,但报告了……、……和……。从Vigibase中检索到了49种天然产物的45,042份ICSR:单一成分产品的有10,702份,多成分产品的有34,340份。在将单一成分产品列为唯一可疑物的7856份报告中,15.8%是SAE,包括8例致命病例。然而,由于数据不足,因果关系仍不明确。……、……和……与SAE最常相关。在多成分产品中,蜂胶经常与超敏反应和皮肤反应有关。
本研究全面概述了具有适应原性和免疫调节作用的天然产物的安全性。产品成分的变异性、缺乏标准化、临床研究报告不完整以及药物警戒数据库报告不足,使得准确的风险评估变得复杂。对于多成分产品,将特定的AE归因于特定成分仍然很困难。需要进一步开展高质量的临床研究并改善药物警戒,同时要有明确的安全警告以降低消费者风险。